drugset / Trial / NCT01412229
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
40 enrolled
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
Timeline
- Start
- 2012-02
- Primary completion
- 2015-06-20
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 100 mg/m2 | Intravenous |